Table 3.
Best overall response in the intention-to-treat population
| Best overall response | Palbociclib plus endocrine therapy (n = 57) | Palbociclib monotherapy |
|---|---|---|
| Complete response | 0 (0) | 0 (0) |
| Partial response | 6 (10) | 4 (7) |
| Stable disease ≥24 weeks | 25 (44) | 31 (53) |
| Stable disease <24 weeks | 7 (12) | 2 (3) |
| Progressive disease | 14 (25) | 17 (29) |
| Not evaluablea | 5 (9) | 4 (7) |
Data are represented as number (%). Stable disease was defined by evidence of stability over a duration of at least 12 weeks.
a
Not evaluable due to absence of post baseline disease assessments.